EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Elevated serum circulating cell‐free mitochondrial DNA in amyotrophic lateral sclerosis

Jieyu Li, Chao Gao, Qingqing Wang, Jing Liu, Zhiying Xie iD, Yawen Zhao, Meng Yu, Yiming Zheng, He Lv, Wei Zhang, Yun Yuan iD, Lingchao Meng und 2 weitere

European Journal of Neurology · 2024-12 · 31 (12)

DOI: 10.1111/ene.16493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 26.09.2024. Verfasst von Jieyu Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, DNA, Mitochondrial, Interleukin-6, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Capitals Funds for Health Improvement and Research, Beijing Nova Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The substantial role of inflammation in amyotrophic lateral sclerosis (ALS) is gaining support from recent research. Studies indicate that circulating cell‐free mitochondrial DNA (ccf‐mtDNA) can activate the immune system and is associated with neurodegenerative diseases. This research was designed to quantify ccf‐mtDNA levels in the serum of ALS patients.

Methods

The medical records of ALS patients were reviewed. Serum ccf‐mtDNA levels of patients with ALS ( n = 62) and age‐matched healthy controls ( n = 46) were measured and compared. Additionally, serum interleukin‐6 (IL‐6) levels were measured using an enzyme‐linked immunosorbent assay in 26 ALS patients. Correlations between variables were analyzed.

Results

Serum ccf‐mtDNA was notably higher in the patients with ALS. When stratified by genotype, the superoxide dismutase 1 ( SOD1 ) mutation group showed the greatest increase in ccf‐mtDNA levels relative to other ALS patients. Among all 108 individuals, a cut‐off set at 1.1 × 10 5 mtDNA copies on a receiver‐operating characteristic curve identified patients with ALS with 80.7% sensitivity and 50.0% specificity; the area under the curve was 0.69 ( p < 0.001). Furthermore, serum ccf‐mtDNA levels correlated negatively with the progression rate of ALS (ΔFS; rs = −0.26, p = 0.044), but not the ALSFRS‐R score ( rs = 0.06, p = 0.625). Importantly, the correlation between ccf‐mtDNA and ΔFS was more pronounced in the SOD1 mutation group ( rs = −0.62, p = 0.018). Lastly, a significant positive association was observed between serum ccf‐mtDNA levels and IL‐6 levels in ALS ( r s= 0.41, p = 0.038).

Conclusion

Our study found increased serum ccf‐mtDNA in ALS patients, suggesting a link to inflammatory processes and disease mechanism. Moreover, ccf‐mtDNA could be an indicator for ALS progression, especially in those with the SOD1 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisDNA, MitochondrialInterleukin-6Cell-Free Nucleic AcidsSuperoxide Dismutase-1HumansMaleFemaleMiddle AgedAgedMutationAdultBiomarkers

Stichwörter der Autor:innen

amyotrophic lateral sclerosiscirculating cell‐free mitochondrial DNAdisease progressioninflammation

Substanzen

DNA, MitochondrialInterleukin-6Cell-Free Nucleic AcidsSuperoxide Dismutase-1SOD1 protein, humanBiomarkersIL6 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Peking University First Hospital, Beijing, China.
  • Beijing Key Laboratory of Neurovascular Disease Discovery, Beijing, China.
  • Key Laboratory for Neuroscience, Ministry of Education/National Health Commission, Peking University, Beijing, China.

ORCID-Profile: Zhiying Xie, Yun Yuan, Jianwen Deng

Förderung

  • National Natural Science Foundation of China
  • Capitals Funds for Health Improvement and Research
  • Beijing Nova Program
  • Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital
  • National High Level Hospital Clinical Research Funding (High Quality Clinical Research Project of Peking University First Hospital

Zitieren

APA

Li, J., Gao, C., Wang, Q., Liu, J., Xie, Z., Zhao, Y., Yu, M., Zheng, Y., Lv, H., Zhang, W., Yuan, Y., Meng, L., Deng, J., & Wang, Z. (2024). Elevated serum circulating cell‐free mitochondrial DNA in amyotrophic lateral sclerosis. European Journal of Neurology, 31(12). https://doi.org/10.1111/ene.16493

Vancouver

Li J, Gao C, Wang Q, Liu J, Xie Z, Zhao Y, et al. Elevated serum circulating cell‐free mitochondrial DNA in amyotrophic lateral sclerosis. European Journal of Neurology. 2024;31(12). doi:10.1111/ene.16493

BibTeX
@article{Li2024,
  author = {Li, Jieyu and Gao, Chao and Wang, Qingqing and Liu, Jing and Xie, Zhiying and Zhao, Yawen and Yu, Meng and Zheng, Yiming and Lv, He and Zhang, Wei and Yuan, Yun and Meng, Lingchao and Deng, Jianwen and Wang, Zhaoxia},
  title = {Elevated serum circulating cell‐free mitochondrial DNA in amyotrophic lateral sclerosis},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {12},
  doi = {10.1111/ene.16493}
}
Kostenlos starten →